JO3485B1 - 4- {4-[(1e)-4-( 2 , 9- داي ازا سبيرو ] 5.5 [ انديك- 2- يل )بيوت -1 – ين-1-يل[ -2-ميثيل بنزيل {- 5-(بروبان-2-يل)- 1h-بيرازول -3-يل بيتا – d – جلوكو بيرانوسيد اسيتيت - Google Patents

4- {4-[(1e)-4-( 2 , 9- داي ازا سبيرو ] 5.5 [ انديك- 2- يل )بيوت -1 – ين-1-يل[ -2-ميثيل بنزيل {- 5-(بروبان-2-يل)- 1h-بيرازول -3-يل بيتا – d – جلوكو بيرانوسيد اسيتيت

Info

Publication number
JO3485B1
JO3485B1 JOP/2014/0310A JOP20140310A JO3485B1 JO 3485 B1 JO3485 B1 JO 3485B1 JO P20140310 A JOP20140310 A JO P20140310A JO 3485 B1 JO3485 B1 JO 3485B1
Authority
JO
Jordan
Prior art keywords
diazaspiro
undec
methylbenzyl
pyrazol
propan
Prior art date
Application number
JOP/2014/0310A
Other languages
English (en)
Inventor
Marie Reutzel-Edens Susan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3485B1 publication Critical patent/JO3485B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمركب له الصيغة I : أو هيدرات منه.
JOP/2014/0310A 2013-11-08 2014-10-26 4- {4-[(1e)-4-( 2 , 9- داي ازا سبيرو ] 5.5 [ انديك- 2- يل )بيوت -1 – ين-1-يل[ -2-ميثيل بنزيل {- 5-(بروبان-2-يل)- 1h-بيرازول -3-يل بيتا – d – جلوكو بيرانوسيد اسيتيت JO3485B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361901488P 2013-11-08 2013-11-08

Publications (1)

Publication Number Publication Date
JO3485B1 true JO3485B1 (ar) 2020-07-05

Family

ID=51982747

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0310A JO3485B1 (ar) 2013-11-08 2014-10-26 4- {4-[(1e)-4-( 2 , 9- داي ازا سبيرو ] 5.5 [ انديك- 2- يل )بيوت -1 – ين-1-يل[ -2-ميثيل بنزيل {- 5-(بروبان-2-يل)- 1h-بيرازول -3-يل بيتا – d – جلوكو بيرانوسيد اسيتيت

Country Status (35)

Country Link
US (1) US9573970B2 (ar)
EP (1) EP3066108B1 (ar)
JP (1) JP6197113B2 (ar)
KR (1) KR101858881B1 (ar)
CN (1) CN105705509B (ar)
AP (1) AP2016009180A0 (ar)
AR (2) AR098670A1 (ar)
AU (1) AU2014347065B2 (ar)
CA (1) CA2925128C (ar)
CL (1) CL2016000791A1 (ar)
CR (1) CR20160165A (ar)
CY (1) CY1121096T1 (ar)
DK (1) DK3066108T3 (ar)
DO (1) DOP2016000067A (ar)
EA (1) EA028801B1 (ar)
ES (1) ES2703944T3 (ar)
HR (1) HRP20182061T1 (ar)
IL (1) IL244899B (ar)
JO (1) JO3485B1 (ar)
LT (1) LT3066108T (ar)
MA (1) MA39019A1 (ar)
MX (1) MX368174B (ar)
MY (1) MY192242A (ar)
NZ (1) NZ718118A (ar)
PE (1) PE20160884A1 (ar)
PH (1) PH12016500851B1 (ar)
PL (1) PL3066108T3 (ar)
PT (1) PT3066108T (ar)
RS (1) RS58050B1 (ar)
SI (1) SI3066108T1 (ar)
SV (1) SV2016005190A (ar)
TN (1) TN2016000112A1 (ar)
TW (1) TWI655198B (ar)
UA (1) UA118767C2 (ar)
WO (1) WO2015069541A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3011733T3 (en) * 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
JP2020523394A (ja) * 2017-06-12 2020-08-06 リグナメッド・エルエルシーLignamed,Llc (s,s)−セコイソラリシレシノールジグルコシド及び(r,r)−セコイソラリシレシノールジグルコシドの製造方法
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
CA2438593C (en) 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
ZA200501094B (en) * 2002-08-08 2006-10-25 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
PL213095B1 (pl) * 2002-08-08 2013-01-31 Kissei Pharmaceutical Pochodna pirazolu, kompozycja farmaceutyczna, srodek do leczenia lub hamowania choroby i zastosowanie pochodnej pirazolu
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
TW200812995A (en) * 2006-05-19 2008-03-16 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound
EP2228378B1 (en) 2007-12-27 2015-09-09 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
SG173801A1 (en) 2009-02-23 2011-09-29 Taisho Pharmaceutical Co Ltd 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
KR20120091174A (ko) 2009-10-02 2012-08-17 사노피 골질환 치료제의 제조를 위한 sglt-1/sglt-2 억제제 활성을 갖는 화합물의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
EP3066108B1 (en) 2018-10-24
MA39019A1 (fr) 2017-04-28
PH12016500851A1 (en) 2016-06-20
AR124083A2 (es) 2023-02-08
HRP20182061T1 (hr) 2019-02-08
MY192242A (en) 2022-08-10
RS58050B1 (sr) 2019-02-28
AP2016009180A0 (en) 2016-04-30
US20160215011A1 (en) 2016-07-28
AU2014347065B2 (en) 2016-09-29
PT3066108T (pt) 2018-11-29
WO2015069541A1 (en) 2015-05-14
PL3066108T3 (pl) 2019-03-29
CA2925128C (en) 2017-10-17
MX368174B (es) 2019-09-23
TW201609783A (zh) 2016-03-16
IL244899A0 (en) 2016-05-31
SV2016005190A (es) 2018-11-01
CR20160165A (es) 2016-06-08
KR101858881B1 (ko) 2018-05-16
NZ718118A (en) 2017-11-24
MX2016005999A (es) 2016-07-22
DK3066108T3 (da) 2019-01-02
CN105705509A (zh) 2016-06-22
PH12016500851B1 (en) 2020-02-19
CL2016000791A1 (es) 2016-11-11
JP2016539099A (ja) 2016-12-15
ES2703944T3 (es) 2019-03-13
CN105705509B (zh) 2018-12-04
IL244899B (en) 2019-10-31
CY1121096T1 (el) 2019-12-11
DOP2016000067A (es) 2016-04-15
EP3066108A1 (en) 2016-09-14
EA201690749A1 (ru) 2016-08-31
AR098670A1 (es) 2016-06-08
SI3066108T1 (sl) 2018-12-31
CA2925128A1 (en) 2015-05-14
PE20160884A1 (es) 2016-09-10
TWI655198B (zh) 2019-04-01
TN2016000112A1 (en) 2017-07-05
JP6197113B2 (ja) 2017-09-13
US9573970B2 (en) 2017-02-21
UA118767C2 (uk) 2019-03-11
LT3066108T (lt) 2019-01-25
AU2014347065A1 (en) 2016-04-07
EA028801B1 (ru) 2017-12-29
KR20160067157A (ko) 2016-06-13

Similar Documents

Publication Publication Date Title
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
IN2015DN00598A (ar)
UA118666C2 (uk) Похідні піразолу
MX2016016405A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas.
MX2015017156A (es) Inhibidores de bace.
MX2015008829A (es) Momelotinib deuterado.
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2016014857A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2016001641A (es) Ciclobutilcarboxamidas como nematicidas.
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
MX2015007309A (es) Derivado de hidantoina.
PH12016500851B1 (en) 4-{4-[(1 e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1 -en-1 -yl]-2-methylbenzyl}-5-(propan-2-yl)-1 h-pyrazol-3-yl beta-d- glucopyranoside acetate
MX374568B (es) Formas sólidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-(pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
MX2012007837A (es) Derivados de oxazolopirimidina 2, 5 - sustituidos.
MX2016006163A (es) Proceso para preparar derivados de 3,5-bis(haloalquil)pirazol a partir de a,a-dihaloaminas.
MX2015016766A (es) Nuevos derivados de tetrazolona.
MX2016006807A (es) Derivados de imidazol.
PH12018501585A1 (en) Novel pyrrolidine derivatives
MX2015012610A (es) Pacritinib deuterizado.
TH1601002568A (th) 4-{4-[(1e)-4-(2,9-ไดอะซะสไพโร[5.5]อันเดค-2-อิล)บิวท์-1-เอ็น-1-อิล]-2- เมธิลเบนซิล}-5-(โพรแพน-2-อิล)-1h-ไพเเรซอล-3-อิล เบทา-d-กลูโคไพแรโนไซด์ แอซิเทท
UA48769U (ru) Применение соединения 3-децилоксикарбонилметил-4-метил-5-(2-гидроксиэтил)тиазолий хлорид как соединения, которое вызывает деполяризацию плазматической мембраны тромбоцитов крови кролика
LV14757A (lv) Arabinofuranozilpurīna nukleozīdu sintēze
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями